Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) insider Keith M. Mcgahan sold 3,735 shares of the business’s stock in a transaction dated Monday, June 21st. The stock was sold at an average price of $4.27, for a total value of $15,948.45. Following the completion of the sale, the insider now directly owns 308,199 shares of the company’s stock, valued at approximately $1,316,009.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
NASDAQ SPPI opened at $3.93 on Thursday. Spectrum Pharmaceuticals, Inc. has a twelve month low of $2.82 and a twelve month high of $5.24. The firm has a market cap of $634.78 million, a PE ratio of -3.30 and a beta of 2.23. The business’s 50-day simple moving average is $3.50.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last issued its quarterly earnings results on Thursday, May 13th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.08. As a group, equities analysts anticipate that Spectrum Pharmaceuticals, Inc. will post -1.01 EPS for the current year.
Separately, B. Riley reissued a “buy” rating and set a $8.00 price objective on shares of Spectrum Pharmaceuticals in a research report on Monday, April 12th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $9.75.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include ROLONTIS, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma.
Featured Story: Trading Halts Explained
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.